Hematopoietic stem cell transplantation in serine/threonine kinase 4 (STK4) deficiency: Report of two cases and literature review

Keyphrases

• Hematopoietic Stem Cell Transplantation 100%
• Serine-threonine Kinase 100%
• Conditioning Regimen 66%
• Sirolimus 50%
• Graft-versus-host Disease Prophylaxis 50%
• Methotrexate 33%
• Rituximab 33%
• Mycophenolate Mofetil 33%
• Busulfan 33%
• Fludarabine 33%
• Combined Immunodeficiency 33%
• Viral Infection 16%
• Graft-versus-host Disease (GvHD) 16%
• Organ Toxicity 16%
• Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT) 16%
• High Mortality 16%
• Favorable Outcome 16%
• First Year 16%
• Early Onset 16%
• Venous Disease 16%
• Curative Treatment 16%
• Fungal Infection 16%
• Unrelated Donor 16%
• Myeloablative 16%
• Same-day 16%
• Recurrent Bacterial Infections 16%
• Donor chimerism 16%
• Peripheral Blood Stem Cells 16%

Immunology and Microbiology

• Conditioning 100%
• Hematopoietic Stem Cell Transplantation 100%
• Graft-Versus-Host Disease 75%
• Sirolimus 75%
• Combined Immunodeficiencies 50%
• Rituximab 50%
• Methotrexate 50%
• Mycophenolate Mofetil 50%
• Acute Graft Versus Host Disease 25%
• Allogeneic Hematopoietic Stem Cell Transplantation 25%
• Chimera 25%
• Peripheral Blood Stem Cell 25%

Pharmacology, Toxicology and Pharmaceutical Science

• Protein Serine Threonine Kinase 100%
• Graft Versus Host Reaction 50%
• Rapamycin 50%
• Busulfan 33%
• Methotrexate 33%
• Rituximab 33%
• Mycophenolate Mofetil 33%
• Combined Immunodeficiencies 33%
• Fludarabine 33%
• Organ Toxicity 16%
• Acute Graft Versus Host Disease 16%
• Vein Occlusion 16%
• Virus Infection 16%
• Bacterial Infection 16%
• Disease 16%
• Mycosis 16%